Repligen Co. (NASDAQ:RGEN) Receives $184.73 Consensus PT from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have received an average recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $186.00.

Several equities research analysts have weighed in on RGEN shares. TD Cowen started coverage on Repligen in a report on Monday. They issued a “buy” rating and a $200.00 price target for the company. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. HC Wainwright lowered their price target on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Wolfe Research started coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company.

Repligen Price Performance

Shares of RGEN stock opened at $153.86 on Thursday. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13. The stock’s 50-day moving average is $155.37 and its 200 day moving average is $148.93. The company has a market cap of $8.62 billion, a P/E ratio of -415.83, a PEG ratio of 4.54 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter last year, the company earned $0.23 earnings per share. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. Research analysts predict that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Champlain Investment Partners LLC raised its position in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after acquiring an additional 850,345 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in Repligen by 0.7% during the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock valued at $136,395,000 after acquiring an additional 6,872 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Repligen by 6.1% during the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after acquiring an additional 36,773 shares in the last quarter. DF Dent & Co. Inc. raised its position in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after acquiring an additional 139,615 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in Repligen by 2.5% during the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock valued at $83,693,000 after acquiring an additional 14,398 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.